Loading stock data…
$7.30-0.42 (-5.44%)
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
Arvinas, Inc. in the Healthcare sector is trading at $7.30 with a market capitalization of $606M. Wall Street consensus targets $13.93 (14 analysts), implying a +90.8% move over the next 12 months. The stock is currently near its 52-week low of $6.74, remaining 25.5% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $249.70M↑ | $15.60M↑ | $9.50M↓ | $41.90M↑ | $22.40M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $164.10M↑ | -$63.80M↑ | -$74.60M↓ | -$43.80M↑ | -$71.50M |
| Net Income | $169.40M↑ | -$57.60M↑ | -$67.40M↓ | -$35.10M↑ | -$61.20M |
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degrad...